| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
DL-Mevalonolactone-d7 has no independent pharmacological target as an isotope tracer. The unlabeled parent compound DL-Mevalonolactone is the delta-lactone form of mevalonic acid, a precursor in the mevalonate pathway. Mevalonic acid is converted to mevalonate-5-phosphate by mevalonate kinase, initiating the biosynthesis of cholesterol, isoprenoids, and other essential metabolites. The deuterated version is used exclusively as an analytical internal standard.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled internal standard, DL-Mevalonolactone-d7 is not tested for classical in vitro pharmacological activity. It is used in cell culture studies as an internal standard added to cell lysates for the quantification of endogenous mevalonolactone and mevalonic acid by LC-MS/MS. The compound co-elutes with the unlabeled analyte and corrects for matrix effects, ion suppression, and extraction recovery without interfering with cellular metabolic processes. |
| ln Vivo |
DL-Mevalonolactone-d7 has no independent in vivo pharmacological activity as a therapeutic agent. It is used in animal and human pharmacokinetic studies as a stable isotope-labeled internal standard added to biological samples for the quantification of endogenous mevalonolactone. The deuterated compound is also employed as a tracer to study the mevalonate pathway and cholesterol biosynthesis in vivo using mass spectrometry-based approaches.
|
| Enzyme Assay |
For in vitro enzyme assays, DL-Mevalonolactone-d7 is dissolved in an appropriate organic solvent (e.g., methanol or DMSO) to prepare stock solutions (1-10 mg/mL). The compound is added as an internal standard to mevalonate kinase or HMG-CoA reductase assay mixtures at a fixed concentration (e.g., 10-100 ng/mL). Following enzymatic reactions and protein precipitation, the samples are analyzed by LC-MS/MS to quantify unlabeled product formation, with the deuterated standard correcting for sample handling and instrument variability.
|
| Cell Assay |
For cell-based LC-MS/MS quantification, cells (e.g., hepatocytes, HepG2, or primary hepatocytes) are cultured in standard medium (DMEM with 10% FBS). Cell lysates or culture supernatants are collected, and a fixed concentration of DL-Mevalonolactone-d7 (e.g., 10-500 ng/mL) is added as an internal standard. Proteins are precipitated with methanol or acetonitrile, and the samples are centrifuged and analyzed by LC-MS/MS to quantify endogenous mevalonolactone levels. The internal standard corrects for matrix effects and extraction recovery.
|
| Animal Protocol |
For in vivo pharmacokinetic studies, DL-Mevalonolactone-d7 is not administered to animals independently. It is used as an internal standard added to plasma or tissue samples obtained from animals treated with experimental compounds affecting the mevalonate pathway (e.g., statins). After sample collection, a fixed concentration of the deuterated internal standard (e.g., 10-500 ng/mL) is added. Following protein precipitation with methanol or acetonitrile and centrifugation, samples are analyzed by LC-MS/MS to determine absolute concentrations of endogenous mevalonolactone.
|
| ADME/Pharmacokinetics |
DL-Mevalonolactone-d7 is an analytical internal standard and does not have independent pharmacokinetic parameters. The unlabeled DL-Mevalonolactone is the delta-lactone form of mevalonic acid, an endogenous metabolite with a short plasma half-life in humans (approximately 10-30 minutes). Mevalonic acid is rapidly phosphorylated in the liver via the mevalonate pathway. The deuterated version is used to calibrate quantitative methods and does not alter the ADME properties of the endogenous analyte.
|
| Toxicity/Toxicokinetics |
DL-Mevalonolactone-d7 is a stable isotope-labeled analytical standard with low toxicity as it is handled at microgram to milligram quantities in research settings. The unlabeled DL-Mevalonolactone is an endogenous metabolite present in all mammalian systems. No specific acute toxicity data is reported for this compound. Standard laboratory safety precautions for handling deuterated organic compounds (gloves, safety glasses, fume hood) are recommended. Not intended for human consumption.
|
| References |
|
| Additional Infomation |
DL-Mevalonolactone-d7 is not a drug but a deuterium-labeled stable isotope internal standard. It has no approved therapeutic status, no clinical trial history as a therapeutic agent, and is not intended for human consumption. This compound is used exclusively as an analytical internal standard for the quantification of mevalonolactone and mevalonic acid by LC-MS/MS or GC-MS in metabolic research, drug development, and biomarker studies. It is also employed as a tracer for studying cholesterol biosynthesis, isoprenoid metabolism, and the effects of HMG-CoA reductase inhibitors (statins). Available with ≥99.0% purity and ≥98 atom% D.
|
| Molecular Formula |
C6H3D7O3
|
|---|---|
| Molecular Weight |
137.18
|
| Exact Mass |
137.107
|
| CAS # |
347840-19-1
|
| Related CAS # |
DL-Mevalonolactone;674-26-0
|
| PubChem CID |
101259392
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
0.074
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC([2H])([2H])C([2H])([2H])C(C([2H])([2H])[2H])(O)C1
|
| InChi Key |
JYVXNLLUYHCIIH-NCKGIQLSSA-N
|
| InChi Code |
InChI=1S/C6H10O3/c1-6(8)2-3-9-5(7)4-6/h8H,2-4H2,1H3/i1D3,2D2,3D2
|
| Chemical Name |
5,5,6,6-tetradeuterio-4-hydroxy-4-(trideuteriomethyl)oxan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2897 mL | 36.4485 mL | 72.8969 mL | |
| 5 mM | 1.4579 mL | 7.2897 mL | 14.5794 mL | |
| 10 mM | 0.7290 mL | 3.6448 mL | 7.2897 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
